SCHEMBL2597683

SCHEMBL2597683

COc1cccc(C(=O)Nc2ccc(CC(=O)O)cc2C(=O)N(C)C)c1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.49
NR1H4 Q96RI1 5/20 0.49
PPARD Q03181 4/20 0.49
PPARG P37231 3/20 0.49
RXFP1 Q9HBX9 3/20 0.48
MTTP P55157 3/20 0.45
PTGDR2 Q9Y5Y4 3/20 0.42
ITGB1 P05556 1/20 0.42
ITGA4 P13612 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
TBXA2R P21731 1/20 0.41
PTGDR Q13258 1/20 0.41
ADAMTS7 Q9UKP4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597977 0.89 NR1H4 (0.51) PPARANR1H4PPARDPPARGMTTP
SCHEMBL2597850 0.84 PPARG (0.53) PPARANR1H4PPARDPPARGMTTP
SCHEMBL3725220 0.84 RXFP1 (0.43) PPARANR1H4PPARDPPARGRXFP1
SCHEMBL2597716 0.82 PSEN1 (0.46) PPARANR1H4PPARDPPARGMTTP
SCHEMBL14777521 0.81 SMO (0.39) PPARANR1H4PPARDPPARGMTTP
SCHEMBL14777753 0.80 MTTP (0.39) PPARANR1H4PPARDPPARGRXFP1
SCHEMBL13580512 0.79 MTTP (0.50) PPARANR1H4PPARDPPARGMTTP
SCHEMBL2597937 0.79 PSEN1 (0.48) PPARANR1H4PPARDPPARGMTTP
SCHEMBL13319033 0.78 MTTP (0.62) PPARANR1H4PPARDPPARGMTTP
SCHEMBL2597813 0.77 MTTP (0.38) RXFP1MTTPPTGDR2ADAMTS7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571860-A1 2-PHENYL BENZOYLAMIDES Pfizer Inc (US) 2013-03-27 EP claimed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US claimed
WO-2011145022-A1 2-PHENYL BENZOYLAMIDES PFIZER INC. (US) 2011-11-24 WO claimed
EP-2571860-A1 2-PHENYL BENZOYLAMIDES Pfizer Inc (US) 2013-03-27 EP disclosed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US disclosed
WO-2011145022-A1 2-PHENYL BENZOYLAMIDES PFIZER INC. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072519-A1 2-PHENYL BENZOYLAMIDES APOB, MTTP, HADHB PPARA 351/4885NR1H4 248/4885PPARD 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.